» Articles » PMID: 24346989

The Effect of Nonsurgical Periodontal Therapy on Hemoglobin A1c Levels in Persons with Type 2 Diabetes and Chronic Periodontitis: a Randomized Clinical Trial

Abstract

Importance: Chronic periodontitis, a destructive inflammatory disorder of the supporting structures of the teeth, is prevalent in patients with diabetes. Limited evidence suggests that periodontal therapy may improve glycemic control.

Objective: To determine if nonsurgical periodontal treatment reduces levels of glycated hemoglobin (HbA1c) in persons with type 2 diabetes and moderate to advanced chronic periodontitis.

Design, Setting, And Participants: The Diabetes and Periodontal Therapy Trial (DPTT), a 6-month, single-masked, multicenter, randomized clinical trial. Participants had type 2 diabetes, were taking stable doses of medications, had HbA1c levels between 7% and less than 9%, and untreated chronic periodontitis. Five hundred fourteen participants were enrolled between November 2009 and March 2012 from diabetes and dental clinics and communities affiliated with 5 academic medical centers.

Interventions: The treatment group (n = 257) received scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months. The control group (n = 257) received no treatment for 6 months.

Main Outcomes And Measures: Difference in change in HbA1c level from baseline between groups at 6 months. Secondary outcomes included changes in probing pocket depths, clinical attachment loss, bleeding on probing, gingival index, fasting glucose level, and Homeostasis Model Assessment (HOMA2) score.

Results: Enrollment was stopped early because of futility. At 6 months, mean HbA1c levels in the periodontal therapy group increased 0.17% (SD, 1.0), compared with 0.11% (SD, 1.0) in the control group, with no significant difference between groups based on a linear regression model adjusting for clinical site (mean difference, -0.05% [95% CI, -0.23% to 0.12%]; P = .55). Periodontal measures improved in the treatment group compared with the control group at 6 months, with adjusted between-group differences of 0.28 mm (95% CI, 0.18 to 0.37) for probing depth, 0.25 mm (95% CI, 0.14 to 0.36) for clinical attachment loss, 13.1% (95% CI, 8.1% to 18.1%) for bleeding on probing, and 0.27 (95% CI, 0.17 to 0.37) for gingival index (P < .001 for all).

Conclusions And Relevance: Nonsurgical periodontal therapy did not improve glycemic control in patients with type 2 diabetes and moderate to advanced chronic periodontitis. These findings do not support the use of nonsurgical periodontal treatment in patients with diabetes for the purpose of lowering levels of HbA1c.

Trial Registration: clinicaltrials.gov Identifier: NCT00997178.

Citing Articles

Pathogenic Mechanisms That May Link Periodontal Disease and Type 2 Diabetes Mellitus-The Role of Oxidative Stress.

Mirnic J, Djuric M, Brkic S, Gusic I, Stojilkovic M, Tadic A Int J Mol Sci. 2024; 25(18).

PMID: 39337292 PMC: 11432179. DOI: 10.3390/ijms25189806.


A Roadmap for the Rational Use of Biomarkers in Oral Disease Screening.

Cirillo N Biomolecules. 2024; 14(7).

PMID: 39062501 PMC: 11274832. DOI: 10.3390/biom14070787.


Association between dental visit behavior and mortality: a nationwide longitudinal cohort study from NHANES.

Xu K, Ma S, Gu J, Liu Q, He Z, Li Y Clin Oral Investig. 2023; 28(1):37.

PMID: 38148418 DOI: 10.1007/s00784-023-05471-8.


Systematic review and meta-analysis of randomized controlled trials evaluating the efficacy of non-surgical periodontal treatment in patients with concurrent systemic conditions.

Joseph P, Prabhakar P, Holtfreter B, Pink C, Suvan J, Kocher T Clin Oral Investig. 2023; 28(1):21.

PMID: 38147183 PMC: 10751251. DOI: 10.1007/s00784-023-05392-6.


Collagenase-Responsive Hydrogel Loaded with GSK2606414 Nanoparticles for Periodontitis Treatment through Inhibiting Inflammation-Induced Expression of PERK of Periodontal Ligament Stem Cells.

Zhou Y, Liu J, Xue P, Zhang J Pharmaceutics. 2023; 15(10).

PMID: 37896262 PMC: 10609791. DOI: 10.3390/pharmaceutics15102503.